New drug combo tested to control advanced prostate cancer
NCT ID NCT07389174
Summary
This early-stage study is testing whether adding an experimental oral drug called LC-K76 to standard hormone therapy helps control metastatic prostate cancer that still responds to hormones. It will involve about 40 men who have not had prior cancer treatment, focusing primarily on safety and initial signs of effectiveness. Participants will take the drug for 24 weeks and be followed for another 24 weeks to monitor their response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER (ADENOCARCINOMA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changzheng hospital
Shanghai, Shanghai Municipality, 201109, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.